Hikal share price
NSE: HIKALPharma & HealthcareDrug Manufacturers - Specialty & Generic
Hikal at a glance
Hikal (NSE: HIKAL) closed at ₹217.00 on 19 Oct 2026, up 0.46% on the day. With a market capitalisation of ₹2,676 Cr, it ranks 1032nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −4.1% in FY26. Over the past year the share price has fallen 12.6%. Its 52-week range is ₹146.25 (30 Mar 2026) to ₹261.00 (4 Dec 2025); the last close is 16.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹400 Cr (+7.7% year on year) and net profit −₹7 Cr, on a consolidated basis. Promoters held 68.85% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,676 CrRank 1032 on NSE
- Price to book
- 1.51×FY26
- EPS (TTM)
- −₹2.74to Q1 FY27
- ROE
- −4.1%FY26
- ROCE
- 4.1%FY26
- Debt to equity
- 0.57FY26
- Net profit margin
- −2.8%FY26
- Book value / share
- ₹97.07FY26
- 52-week high
- ₹261.004 Dec 2025
- 52-week low
- ₹146.2530 Mar 2026
- 1-year return
- −12.6%
- RSI (14-day)
- 48.5
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.46% | +1.9% | −3.6% | −4.9% | −12.6% |
Hikal quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹453 Cr | ₹439 Cr | ₹550 Cr | ₹371 Cr | ₹316 Cr | ₹491 Cr | ₹517 Cr | ₹400 Cr |
| Revenue YoY | +5.0% | +0.1% | +7.3% | −8.0% | −30.2% | +11.8% | −6.0% | +7.7% |
| Net profit | ₹18 Cr | ₹17 Cr | ₹50 Cr | −₹22 Cr | −₹35 Cr | −₹6 Cr | ₹14 Cr | −₹7 Cr |
| Net profit YoY | +45.6% | +6.6% | +47.8% | −539.2% | −290.7% | −134.3% | −71.3% | — |
| Net margin | 4.0% | 3.9% | 9.1% | −6.0% | −11.0% | −1.2% | 2.8% | −1.9% |
| EPS | ₹1.48 | ₹1.39 | ₹4.07 | −₹1.82 | −₹2.83 | −₹0.48 | ₹1.17 | −₹0.60 |
Hikal financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,720 Cr | ₹1,943 Cr | ₹2,023 Cr | ₹1,785 Cr | ₹1,860 Cr | — |
| Operating profit | ₹206 Cr | ₹219 Cr | ₹105 Cr | ₹96 Cr | ₹124 Cr | — |
| Net profit | ₹133 Cr | ₹161 Cr | ₹78 Cr | ₹70 Cr | ₹91 Cr | — |
| EPS (₹) | ₹11.00 | ₹13.00 | ₹6.00 | ₹6.00 | ₹7.00 | — |
| Cash from operations | ₹229 Cr | ₹294 Cr | ₹315 Cr | ₹187 Cr | ₹280 Cr | — |
| Total debt | ₹263 Cr | ₹287 Cr | ₹490 Cr | ₹423 Cr | ₹367 Cr | ₹373 Cr |
| Shareholders' equity | ₹933 Cr | ₹1,068 Cr | ₹1,133 Cr | ₹1,188 Cr | ₹1,262 Cr | ₹1,199 Cr |
Hikal shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| Foreign institutions | 5.69% | 5.36% | 4.23% | 2.30% | 1.43% | 0.99% |
| Domestic institutions | 3.80% | 4.02% | 5.16% | 7.05% | 7.20% | 7.24% |
| Non-institutions | 21.66% | 21.77% | 21.76% | 21.79% | 22.52% | 22.93% |
Hikal vs peers
The listed Pharma & Healthcare companies nearest to Hikal by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SHUKRAPHARShukra Pharma | ₹68.40 | −0.87% | — | ₹3,007 Cr | 136.8 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹262.85 | −1.61% | −14.9% | ₹2,943 Cr | 17.4 | — |
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹217.00 | +0.46% | −12.6% | ₹2,676 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,083.50 | +0.46% | — | ₹2,457 Cr | — | — |
| ALEMBICLTDAlembic | ₹95.20 | −2.46% | −2.8% | ₹2,445 Cr | 7.7 | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
Ask anything about Hikal
Pivot answers on the live chart with evidence you can check, and tests strategies against HIKAL's own history. Try: “Why has HIKAL moved over the last three months?” · “Backtest a 50-day moving-average crossover on HIKAL over five years” · “Compare HIKAL with SHUKRAPHAR on margins and valuation”
Frequently asked questions about Hikal
What is the share price of Hikal today?
Hikal (NSE: HIKAL) last closed at ₹217.00 on 19 Oct 2026. Its 52-week high is ₹261.00 and its 52-week low is ₹146.25.
What is the market cap of Hikal?
Hikal's market capitalisation is ₹2,676 Cr (₹2,676 Cr) at the 19 Oct 2026 close, ranking 1032nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Hikal?
Return on equity was −4.1% in FY26 and return on capital employed was 4.1% in FY26 (consolidated figures).
Is Hikal a debt-free company?
No. Hikal's debt-to-equity ratio was 0.57 in FY26, with total debt of ₹373 Cr.
What were Hikal's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Hikal reported revenue of ₹400 Cr, +7.7% year on year, and net profit of −₹7 Cr.
How has Hikal stock performed over the last year?
Hikal's share price has fallen 12.6% over the past year, −4.9% over three months and −3.6% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Hikal?
As of 30 Jun 2026: promoters 68.85%, foreign institutions 0.99%, domestic institutions 7.24%, non-institutions 22.93%.
Who are Hikal's competitors?
The listed Pharma & Healthcare companies closest to Hikal by market cap are Shukra Pharma, Advanced Enzyme Technologies, Dishman Pharma, Dr Agarwals Eye Hospital, Alembic and Venus Remedies.
Is Hikal a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Hikal's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HIKAL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with H · all NSE stocks · this page as text